Objective: Whether H. pylori eradication in peptic ulcer disease (PUD) patients leads to a decrease in symptoms and use of anti-dyspeptic drugs is questioned. Therefore, the recurrence rate of H. pylori, upper abdominal symptoms, and the use of acidsuppressive drugs were determined 6 years after successful triple therapy. Results: 90 of the 113 eligible patients could be included. The mean follow-up time was 6.0 years (range 4.6-7.6 years). In one patient H. pylori recurred (recurrence rate:
Introduction.
All patients with Helicobacter pylori (H. pylori) related peptic ulcer disease (PUD) should be treated for the infection as this approach cures the ulcer and prevents ulcer relapse (1, 2) . As shown by several long-term follow-up studies, recurrence of H. pylori after successful treatment is very rare in the Western world (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . It mostly happens after the use of a treatment regimen with low efficacy and in the first year after treatment, suggesting that in most cases recurrence represents a missed treatment failure rather than a true reinfection (13) . This notion is supported by studies using DNA fingerprinting of the H. pylori strains isolated before and after treatment (14) (15) (16) .
Although recurrence of the infection is exceptionally rare, it is still debated whether or not eradication of H. pylori in PUD patients leads to a persistent reduction in upper abdominal symptoms and a diminished need for acid suppressing medication. In two studies the majority of PUD patients who were cured from the infection still had upper abdominal symptoms (17, 18) . Furthermore, in the study of Labenz et al. 26% of duodenal ulcer patients developed reflux esophagitis within three years after successful H. pylori eradication (19) .
The purpose of this long-term follow-up study was to determine the recurrence rate of H. pylori in a cohort of Dutch PUD patients. The second aim of the study was to evaluate the long-term effects of anti-H. pylori treatment on upper abdominal symptoms, quality of life, and need for acid suppressive agents. Finally, as it is unknown to what extent anti-H. pylori antibodies remain detectable more than 5 years after treatment, IgA and IgG antibody values were determined in all patients.
Patients and methods.
One hundred and thirteen PUD patients (80 with duodenal ulcer, 29 with gastric ulcer, and 4 with both gastric and duodenal ulcer) were eligible for the study. All patients were treated for their H. pylori infection between May 1990 and October 1993 with a fifteenday course of colloidal bismuth subcitrate 120mg, tetracycline 250mg, and metronidazole 250mg (all four times daily) and were H. pylori negative by histology, urease test, and culture of antral biopsy specimens at follow-up endoscopy three months after treatment (20) . All patients were contacted between April 1997 and November 1998. If the patients were willing to participate, they were asked to complete a previously validated quality of life questionnaire (RAND-36) (21, 22) and to fill out a form evaluating any present and past upper abdominal complaints and their overall assessment of the anti-H. pylori treatment using a four point semi-quantitative scale.
The results of the quality of life questionnaire were compared with a historical control group consisting of a random sample of 1063 subjects from a town located in the same region of the Netherlands (21, 22 At endoscopy antral and corpus biopsy samples were taken for H. pylori culture, urease testing, and histology as described previously (23).
All patients gave written informed consent and the local ethics committee approved the study.
Results.
Ten of the 113 eligible patients had died of unrelated diseases during the follow-up period, four were unable to visit the clinic because of unrelated illnesses, four could not be traced, and five refused to participate in the study. Therefore, 90 patients (80%; 47 147 males; mean age ± standard deviation: 58 ± 12 years) were included. The mean followup time was 6.0 years (range 4.6-7.6) including a total of 540.3 patient-years. 18 of the 90 patients underwent endoscopy for clinical reasons during the follow-up period, in none of these patients H. pylori had recurred and no duodenal or gastric ulcer was found.
In 84 patients a 13 C-urea breath test was performed and the other six underwent endoscopy as the primary investigation. 13 C-urea breath tests were negative in all but two patients. One of them was treated with immunosuppressive drugs after a renal transplant. This patient had only minor upper abdominal symptoms (classified as "B" in Data are presented as number of patients (percentage). retrospectively judged the eradication therapy to have been successful (table 2) . Of the 16 patients still having symptoms one had a recurrent infection, four had gastroesophageal reflux disease (GERD), three had a normal endoscopy, and eight patients refused endoscopy. Two of these patients were regularly using non-steroidal anti-inflammatory drugs (one with a normal endoscopy, one refusing endoscopy).
Before triple therapy all but two patients (98%) used H 2 -receptor antagonists (H 2 RA) and 49 of them (54%) were on maintenance treatment. In all patients but one, data on the use of medication during the years (median 2.8 years, range 1.0-5.9 years) before the follow-up visit were available. Twenty-seven patients (30%) had been prescribed some medication for upper abdominal symptoms during that period but only 12 of them (13%) were on some form of maintenance treatment (H 2 RA in 7 and PPI in 5). The odds ratio for maintenance therapy in patients after successful eradication compared to before Six of the 90 patients had erosive esophagitis at the pre-treatment endoscopy. At followup endoscopy three months after treatment, esophagitis had healed in one of them, but 150 in the five others erosive esophagitis was still present. Four other patients had developed erosive esophagitis at three months. Of the 18 patients that later underwent an endoscopy for clinical reasons three patients had developed erosive esophagitis. As stated above six patients underwent endoscopy as part of the study and in four of them erosive esophagitis was found, two of whom were already known to have esophagitis.
Thus, at least 9 of the 90 patients (10%, 95% confidence interval: 5-18%) developed reflux esophagitis after H. pylori eradication and at least 14 patients (16%, 95%
confidence interval: 9-25%) were likely to have GERD at follow-up. As shown in table   3 , six of the patients on maintenance treatment had GERD. Five were those that had developed GERD after the triple therapy, the other patient was known with GERD before the start of the triple therapy.
When the quality of life of our patients was compared with that of the control group no relevant differences were found in any of the items (physical functioning, social functioning, role physical, role mental, mental health, energy, pain, general health perception, and changes in health status). Our patient group, however, was not Cumulative number of patients AU/mL IgG IgA completely comparable with this control group as it contained fewer females (48% vs. 65%) and was older (mean age: 58 years vs. 44 years).
The median IgG antibody value in the H. pylori negative patients after a mean 6.0 years after treatment was 11.8 AU/ml with a range of 0.3-155.5 AU/ml. In 21 patients (24%, 95% confidence interval: 15-34%) levels were still above the cut-off. The median IgA value was 20.7 AU/ml (range: 3.8-300 AU/mL) and 45 patients (51%, 95% confidence interval: 40-62%) had levels above the cut-off ( figure 1 ). The patient with a recurrent infection had an IgG and IgA value of 261.8 and 63.8 AU/ml, respectively.
Discussion.
Our six-year follow-up study confirms several earlier observations that recurrence of H.
pylori after successful treatment is very rare in the western world (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . A recurrence rate of 0.19% per patient-year is in line with these earlier studies that found figures ranging from 0% to 11%. The study also showed that in patients with PUD upper abdominal symptoms are persistently reduced after successful anti-H. pylori treatment.
Six years after such treatment 53% of the patients did not have upper abdominal symptoms anymore. Another 29% had only minor symptoms and 90% of the patient group was satisfied with the treatment in the long run. Moreover, there was no relevant difference in their quality of life as compared with a random sample of the general population. These data, therefore, suggest that the large majority of these PUD patients were indeed cured from their formerly chronic disease by treatment of the H. pylori infection. This is in concurrence with many studies showing that H. pylori eradication prevents ulcer relapse (1, 2, 25) .
The reduction in symptoms also caused a reduction in use of anti-dyspeptic medication.
Although 30% of the patients used some kind of drugs for dyspepsia during the years preceding follow-up, only a minority (13%) was on maintenance treatment with acid suppressive drugs. H 2 RA have only become available over-the-counter in 1997 in the Netherlands and are still quite expensive. Therefore, the use of over-the-counter acid suppressive drugs is probably of no influence on our results. Approximately half of the patients on maintenance therapy with acid suppressive drugs had documented GERD, in most of the other subjects the reason for maintenance therapy was less clear, although these drugs were of benefit according to the majority of patients.
A minority of our patients still had significant upper abdominal symptoms. In one of them H. pylori had recurred and in four GERD was diagnosed at a previous occasion or 152 at follow-up. In the remaining 11 patients the cause of the persistent complaints was unknown, although two of them were frequently using non-steroidal anti-inflammatory drugs. These findings should be viewed in the light of the prevalence of dyspepsia in the H. pylori-negative part of the general population. A study in apparently healthy volunteers with a mean age of 42 years showed that up to 35% of the H. pylori negatives had dyspeptic symptoms (27) pylori eradication is warranted in all patients with peptic ulcer disease (1,2). Our study supports these conclusions and shows that also in the long run the majority of patients remain H. pylori negative, are satisfied with the treatment, have less upper abdominal symptoms and use less drugs for these symptoms.
The third part of our study shows that 6 years after successful treatment an important proportion of patients remains seropositive. To our knowledge, only one other study describes long-term serological follow-up. Our data are in concurrence with this study that showed that 4 years after successful therapy a large proportion of the patients remains seropositive (28) . Although in our study the IgG assay performs somewhat better then the IgA assay, both tests are unreliable in diagnosing a recurrent H. pylori infection, even as long as six years after treatment.
In summary, our study shows that the recurrence rate of H. pylori after triple therapy in PUD patients is very low. Furthermore, H. pylori eradication for PUD leads to an important reduction in upper abdominal symptoms and reduction in prescriptions for these symptoms. Nevertheless, 10% of the patients are still on maintenance therapy with acid suppressive drugs. Finally, our study shows that IgG and IgA antibody values remain elevated in a large proportion of patients.
